Apricus Biosciences, Inc. (“Apricus Bio”) is a US-based pharmaceutical company that develops innovative treatments for Erectile Dysfunction (ED) & Female Sexual Arousal Disorder (FSAD).
Lead products and products candidate:
Development Stage
Approved in Europe and Canada as first line therapy for the entire patient population.
Main Indication & Description of Product
Topical, single-use product for the treatment of Erectile Dysfunction. Topical application mitigates systemic side effects and has a broader base of potential patients than ingested treatments. Already partnered with Abbott, Sandoz-Novartis, Takeda, Warner-Chilcott, Bracco, Elis, and Neopharm
Territories Available for Out-Licensing
Select European Territories, Russia(CIS), Turkey, Latin America, Asia and Africa. Market estimated to be $2.5 billion ex-US
Development Stage
Phase III in China completed. US based clinical program plan being finalized. Pre-trial meeting with certain regulatory agencies to being scheduled
Main Indication & Description of the Product
Product for the treatment for Female Sexual Arousal Disorder
Territories Available for Out-Licensing
Worldwide rights available. Market estimated to be $2-4 billion worldwide
Product development and partnering opportunities available in various fields throughout the world.
